{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:48:43Z","timestamp":1787960923107,"version":"build-2784847793"},"reference-count":53,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","award":["1802226"],"award-info":[{"award-number":["1802226"]}],"id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Treatment for Adolescents with Depression Study (TADS) continues to influence international clinical practice guidelines for adolescent depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We assessed TADS\u2019 effectiveness and harms through a Restoring Invisible and Abandoned Trials (RIAT)-led reanalysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      TADS was a phase-three multicentre, parallel four-arm randomised controlled superiority trial that randomised adolescents (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 439) to fluoxetine alone (FLX), CBT alone (CBT), open-label fluoxetine plus CBT (COMB) or placebo pill alone (PBO) over 12\u00a0weeks. COMB and CBT groups were unblinded to their treatment allocation. Primary outcomes were the Children\u2019s Depression Rating Scale-Revised (CDRS-R) and Clinical Global Impression-Improvement scale (CGI-I).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our ITT reanalysis showed a significant decrease in CDRS-R at 12\u00a0weeks in COMB compared with PBO (\u22126.65;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) and CBT (\u22127.63,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), but not FLX (\u22124.07,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.063). There was no difference between FLX, CBT and PBO. There was a higher proportion of CGI-I responders in COMB (73.72% [SE 4.43]) compared with all other arms: FLX (64.16% [SE 4.76]), CBT (51.06% [SE 5.29]) and PBO (38.76% [SE 4.87]; all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001); FLX had more responders than PBO (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.004). 369 adverse events were reported for 171 participants, with 66% occurring in those taking fluoxetine. We found 32 serious adverse events (22 in those taking fluoxetine), which varied from original authors\u2019 reporting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our reanalysis replicated the original investigators\u2019 reporting that COMB demonstrated the most robust outcomes and that FLX was not superior to PBO. In contrast to the original TADS Team\u2019s reporting, there was a higher level of harm uncovered in allocation groups taking fluoxetine, including 11 unreported suicide-related adverse events. Overall, the marked increase in harms among participants taking fluoxetine warrants further circumspection when prescribing it to adolescents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251337879","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:38:57Z","timestamp":1748331537000},"page":"218-237","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Restoring TADS: RIAT reanalysis of the Treatment for Adolescents with Depression Study"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-2878","authenticated-orcid":false,"given":"Natalie","family":"Aboustate","sequence":"first","affiliation":[{"name":"The University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Jureidini","sequence":"additional","affiliation":[{"name":"The University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woodman","sequence":"additional","affiliation":[{"name":"Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Le Noury","sequence":"additional","affiliation":[{"name":"Bangor University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Klau","sequence":"additional","affiliation":[{"name":"The University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-9758","authenticated-orcid":false,"given":"Elia","family":"Abi-Jaoude","sequence":"additional","affiliation":[{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Raven","sequence":"additional","affiliation":[{"name":"The University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/00048674211067720"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.03.022"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013674.pub2"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710755115"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.7.807"},{"key":"e_1_3_6_7_2","volume-title":"Protocol: treatment for adolescents with depression study (TADS)","author":"National Institute of Mental Health","year":"2000","unstructured":"National Institute of Mental Health. Protocol: treatment for adolescents with depression study (TADS); version 8 dated 4 january 2000. National Institute of Mental Health. Bethesda: NIMH, 2000. https:\/\/tads.dcri.org\/wp-content\/uploads\/2015\/11\/TADS_Protocol.pdf"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.Chi.0000046839.90931.0d"},{"issue":"12","key":"e_1_3_6_9_2","first-page":"1575","article-title":"Childhood and adolescent depression: a review of the past 10 years. Part II","volume":"35","author":"Birmaher B","year":"1996","unstructured":"Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part II. JAACAP 1996; 35(12): 1575\u20131583.","journal-title":"JAACAP"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830210125017"},{"key":"e_1_3_6_11_2","first-page":"25","article-title":"Psychosocial interventions for adolescent depression: issues, evidence, and future directions","volume":"30","author":"Hoberman H","year":"1996","unstructured":"Hoberman H, Clarke G, Saunders S. Psychosocial interventions for adolescent depression: issues, evidence, and future directions. Prog Behav Modif 1996; 30: 25\u201373.","journal-title":"Prog Behav Modif"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1510-8_15"},{"issue":"1","key":"e_1_3_6_13_2","first-page":"26","article-title":"Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis","volume":"37","author":"Reinecke MA","year":"1998","unstructured":"Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. JAACAP 1998; 37(1): 26\u201334.","journal-title":"JAACAP"},{"issue":"6","key":"e_1_3_6_14_2","first-page":"785","article-title":"Recurrence of major depressive disorder in hospitalized children and adolescents","volume":"36","author":"Emslie GJ","year":"1997","unstructured":"Emslie GJ, Rush AJ, Weinberg WA, et al. Recurrence of major depressive disorder in hospitalized children and adolescents. JAACAP 1997; 36(6): 785\u2013792.","journal-title":"JAACAP"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1998)7:1<32::AID-DA4>3.0.CO;2-7"},{"key":"e_1_3_6_16_2","first-page":"3","article-title":"Child and adolescent psychopharmacology: expanding the research base","volume":"30","author":"Jensen PS","year":"1994","unstructured":"Jensen PS, Vitiello B, Leonard HL, et al. Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull 1994; 30: 3\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7478.1343-d"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7468.748"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7493.730-b"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-0325"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2865"},{"key":"e_1_3_6_22_2","first-page":"346","article-title":"Rapid response: call to action: RIAT reanalysis of TADS: treatment for adolescents with depression study","volume":"2013","author":"Jureidini J","year":"2018","unstructured":"Jureidini J. Rapid response: call to action: RIAT reanalysis of TADS: treatment for adolescents with depression study. BMJ 2018; 2013: 346. https:\/\/www.bmj.com\/content\/346\/bmj.f2865\/rr-3","journal-title":"BMJ"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.15154\/1504156"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-210022"},{"key":"e_1_3_6_25_2","volume-title":"Clarifications and administrative changes to the TADS protocol","author":"National Institute of Mental Health","year":"2001","unstructured":"National Institute of Mental Health. Clarifications and administrative changes to the TADS protocol. Bethesda, MD: NIMH, 2001."},{"key":"e_1_3_6_26_2","volume-title":"Study record: treatment for adolescents with depression study (TADS)","author":"National Institute of Mental Health","unstructured":"National Institute of Mental Health. Study record: treatment for adolescents with depression study (TADS). US National Library of Medicine. Last Updated: 17 April 2014: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00006286?term=treatment+for+adolescents+with+depression&cntry=US&draw=2&rank=1"},{"key":"e_1_3_6_27_2","volume-title":"Treatment for adolescents with depression study (TADS) pharmacotherapy treatment manual","author":"TADS Team","year":"2005","unstructured":"TADS Team. Treatment for adolescents with depression study (TADS) pharmacotherapy treatment manual. Durham, NC: Duke University Medical Center, 2005. https:\/\/tads.dcri.org\/wp-content\/uploads\/2015\/11\/TADS_PT_Manual.pdf"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/00048674231218623"},{"key":"e_1_3_6_29_2","volume-title":"Adverse event monitoring and adjunctive services and attrition prevention (ASAP) in the NIMH treatment of adolescents with depression study (TADS): AE\/ASAP manual","author":"TADS Team","year":"2005","unstructured":"TADS Team. Adverse event monitoring and adjunctive services and attrition prevention (ASAP) in the NIMH treatment of adolescents with depression study (TADS): AE\/ASAP manual. Durham, NC: Duke University Medical Center, 2005. https:\/\/www.psychiatry.wisc.edu\/wp-content\/uploads\/2019\/01\/TADS_Suicide_Prevention_Manual.pdf"},{"key":"e_1_3_6_30_2","volume-title":"Children's depression rating scale, revised (CDRS-R) Manual","author":"Poznanski EO","year":"1996","unstructured":"Poznanski EO, Mokros HB. Children's depression rating scale, revised (CDRS-R) Manual. 6th ed. Los Angeles: Western Psychological Services, 1996.","edition":"6"},{"key":"e_1_3_6_31_2","volume-title":"Independent evaluator (IE) manual: treatment for adolescents with depression study (TADS)","author":"TADS Team","year":"2005","unstructured":"TADS Team. Independent evaluator (IE) manual: treatment for adolescents with depression study (TADS). Durham, NC: Duke University Medical Center, 2005. https:\/\/tads.dcri.org\/wp-content\/uploads\/2015\/11\/TADS_IE_Manual.pdf"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e3180323342"},{"key":"e_1_3_6_34_2","volume-title":"Procedures for managing suicidality in the NIMH treatment of adolescents with depression study (TADS)","author":"TADS Team","year":"2005","unstructured":"TADS Team. Procedures for managing suicidality in the NIMH treatment of adolescents with depression study (TADS). Durham, NC: Duke University Medical Center, 2005. https:\/\/tads.dcri.org\/wp-content\/uploads\/2015\/11\/TADS_Suicide_Prevention_Manual.pdf"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4320"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-160728"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.08m04607"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000240840.63737.1d"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d40"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12131"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2577-a"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-150645"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048279"},{"key":"e_1_3_6_45_2","volume-title":"Healthy Skepticism International News","author":"Parry P","year":"2006","unstructured":"Parry P. Don\u2019t judge a paper by its abstract. In: Healthy Skepticism International News. Healthy Skepticism Org, 2006."},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","unstructured":"March JC. Treatment for adolescents with depression study (TADS)\/Substance use and other outcomes following treatment for adolescent depression (SOFTAD). National Institute of Mental Health Data Archive. DOI: 10.15154\/1504156.","DOI":"10.15154\/1504156"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000240838.78984.e2"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000237710.73755.14"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(19)30215-9"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta12140"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.3233\/jrs-160671"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1132"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286159603000228"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-364"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251337879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251337879","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251337879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:45Z","timestamp":1777509945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251337879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/09246479251337879"],"URL":"https:\/\/doi.org\/10.1177\/09246479251337879","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}